A detailed history of Centaurus Financial, Inc. transactions in Alkermes Plc. stock. As of the latest transaction made, Centaurus Financial, Inc. holds 42,752 shares of ALKS stock, worth $1.27 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
42,752
Previous 38,830 10.1%
Holding current value
$1.27 Million
Previous $935,000 27.91%
% of portfolio
0.08%
Previous 0.07%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$23.01 - $28.55 $90,245 - $111,973
3,922 Added 10.1%
42,752 $1.2 Million
Q2 2024

Sep 20, 2024

BUY
$23.21 - $27.24 $5,477 - $6,428
236 Added 0.61%
38,830 $935,000
Q1 2024

May 14, 2024

BUY
$26.4 - $32.56 $1.02 Million - $1.26 Million
38,594 New
38,594 $1.04 Million
Q3 2018

Nov 05, 2018

SELL
$38.6 - $46.12 $34,740 - $41,508
-900 Closed
0 $0
Q2 2018

Aug 15, 2018

BUY
$40.56 - $51.36 $36,504 - $46,224
900 New
900 $37,000

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.87B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Centaurus Financial, Inc. Portfolio

Follow Centaurus Financial, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Centaurus Financial, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Centaurus Financial, Inc. with notifications on news.